EGFR and non-small cell lung carcinoma: The patient’s medical history revealed that, in 2018, he received a diagnosis of non-small-cell lung cancer (NSCSL) EGFR+ with multiple bone metastases, treated with Osimertinib from 2020 and Denosumab (Xgeva 120 mg IM; one administration every 28 days) from October 2020 to February 2022.